San Francisco, CA, United States of America

Michael S German

This inventor holds 17 USPTO granted patents and 1 published patent application, primarily in Gene Therapy Techniques. Top assignees: University of California, Other. Active years: 1998-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael S German. Retrieved from https://idiyas.com/inventor/michael-s-german

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17 

% Patents Active = 70.6

Average Co-Inventor Count = 2.2

ph-index = 7

Forward Citations = 181(Granted Patents)


Location History:

  • San Francisco, CA (US) (1998 - 2004)
  • Daly City, CA (US) (2005 - 2012)

Company Filing History:


Years Active: 1998-2012

Loading Chart...
Areas of Expertise:
Polynucleotides
Gene Delivery
Insulin Delivery
Therapeutic Gene Products
Secretory Gland Expression
Transgenic Mouse Models
Adenovirus-assisted Transfection
Pancreatic Islet Cells
Neurogenin3
NKX-6.1
Protein Delivery
Intestinal Cell Expression
17 patents (USPTO):Explore Patents

Title: **Michael S German: Innovator in Diabetes Research**

Introduction

Michael S German is a renowned inventor based in San Francisco, CA, recognized for his significant contributions in the field of diabetes research. With an impressive portfolio of 17 patents, he has been instrumental in advancing medical technologies aimed at providing solutions for diabetes mellitus.

Latest Patents

Among his recent innovations are two notable patents centered on the production of pancreatic islet cells and insulin delivery. The first patent, titled "Polynucleotides comprising Neurogenin3 promoter and bHLH encoding domains," focuses on polypeptides exhibiting the activity of human neurogenin3 (hNgn3). This invention outlines the use of islet transcription factors like hNgn3 to aid in the production of pancreatic islet cells from progenitor cells, potentially enhancing insulin delivery through the resultant islet cells.

The second patent emphasizes methods for the production of islet cells and the expression of islet transcription factors in the pancreas. It introduces methods to encourage the expression of nucleic acids encoding neurogenin3 or factors inducing its expression, with the goal of producing new β-cells to treat patients suffering from diabetes mellitus.

Career Highlights

Throughout his career, Michael S German has had affiliations with distinguished institutions, notably the University of California. His extensive work in diabetes research has led to groundbreaking advancements, further solidifying his reputation as a leading inventor in the medical field.

Collaborations

German has collaborated with esteemed colleagues Ira D Goldfine and Stephen S Rothman, which has undoubtedly enhanced the innovative capacities and impact of his work. These partnerships reflect the collaborative nature of scientific research, particularly in developing solutions for complex health challenges like diabetes.

Conclusion

Michael S German's work continues to impact the landscape of diabetes treatment. With his numerous patents and collaborative efforts, he remains a pivotal figure in the quest for optimal strategies in insulin delivery and pancreatic cell production. His dedication to innovation is not only noteworthy, but also inspiring for future inventors and researchers in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…